āđāļāļīāđāļĄāļāļķāđāļ
#JAGSNPHARM Ready for a potential breakout !ð

PROS :
âïļ- Company is almost debt free.
âïļ-Company has delivered good profit growth of 35.2% CAGR over last 5 years
âïļ-Company has been maintaining a healthy dividend payout of 40.0%
âïļ-Company's working capital requirements have reduced from 46.6 days to 35.6 days
Technical View :
ð- Base breakout & again consolidating in small base.
ð- Price Respecting 20 & 50 EMA
ð- Breakout above 490ð
ð- 45% upthrust seen in stock recently.
ð- RR Favorable for going long.
Don't forget to hit thatâĪïļfor a likeðfor a share,andðfor a bookmark!
âïļ- Company is almost debt free.
âïļ-Company has delivered good profit growth of 35.2% CAGR over last 5 years
âïļ-Company has been maintaining a healthy dividend payout of 40.0%
âïļ-Company's working capital requirements have reduced from 46.6 days to 35.6 days
Technical View :
ð- Base breakout & again consolidating in small base.
ð- Price Respecting 20 & 50 EMA
ð- Breakout above 490ð
ð- 45% upthrust seen in stock recently.
ð- RR Favorable for going long.
Don't forget to hit thatâĪïļfor a likeðfor a share,andðfor a bookmark!
āļāļģāļāļģāļāļąāļāļŠāļīāļāļāļīāđāļāļ§āļēāļĄāļĢāļąāļāļāļīāļāļāļāļ
āļāđāļāļĄāļđāļĨāđāļĨāļ°āļāļāļāļ§āļēāļĄāđāļĄāđāđāļāđāļĄāļĩāļ§āļąāļāļāļļāļāļĢāļ°āļŠāļāļāđāđāļāļ·āđāļāļāđāļāđāļŦāđāđāļāļīāļāļāļīāļāļāļĢāļĢāļĄāļāļēāļāļāļēāļĢāđāļāļīāļ, āļāļēāļĢāļĨāļāļāļļāļ, āļāļēāļĢāļāļ·āđāļāļāļēāļĒ, āļāđāļāđāļŠāļāļāđāļāļ° āļŦāļĢāļ·āļāļāļģāđāļāļ°āļāļģāļāļĢāļ°āđāļ āļāļāļ·āđāļ āđ āļāļĩāđāđāļŦāđāļŦāļĢāļ·āļāļĢāļąāļāļĢāļāļāđāļāļĒ TradingView āļāđāļēāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļĩāđ āļāđāļāļāļģāļŦāļāļāļāļēāļĢāđāļāđāļāļēāļ
āļāļģāļāļģāļāļąāļāļŠāļīāļāļāļīāđāļāļ§āļēāļĄāļĢāļąāļāļāļīāļāļāļāļ
āļāđāļāļĄāļđāļĨāđāļĨāļ°āļāļāļāļ§āļēāļĄāđāļĄāđāđāļāđāļĄāļĩāļ§āļąāļāļāļļāļāļĢāļ°āļŠāļāļāđāđāļāļ·āđāļāļāđāļāđāļŦāđāđāļāļīāļāļāļīāļāļāļĢāļĢāļĄāļāļēāļāļāļēāļĢāđāļāļīāļ, āļāļēāļĢāļĨāļāļāļļāļ, āļāļēāļĢāļāļ·āđāļāļāļēāļĒ, āļāđāļāđāļŠāļāļāđāļāļ° āļŦāļĢāļ·āļāļāļģāđāļāļ°āļāļģāļāļĢāļ°āđāļ āļāļāļ·āđāļ āđ āļāļĩāđāđāļŦāđāļŦāļĢāļ·āļāļĢāļąāļāļĢāļāļāđāļāļĒ TradingView āļāđāļēāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļĩāđ āļāđāļāļāļģāļŦāļāļāļāļēāļĢāđāļāđāļāļēāļ